Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

39 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-12

Study Completion Date

2021-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain that the investigators determine to be healthier, more mature, and less traumatized. Investigators will compare an active and a sham treatment given twice weekly for 4-weeks. Investigators hope this will lead to a significant weapon in the battle against the opioid epidemic as well as lead to psychological and physiological insights into possible relations among trauma, cerebral laterality, and addiction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Project to Test the Efficacy and Safety of An Innovative Treatment for Opiate Use Disorders.

NCT05995873

Opioid Use Disorder, Moderate Opioid Use Opioid Dependence +3 more

UNKNOWN NA

Transcranial Photobiomodulation for the Treatment of Opioid Cravings

NCT04417738

Opioid-use Disorder Depression, Anxiety Craving

COMPLETED NA

Adjunctive Bright Light Therapy for Opioid Use Disorder

NCT05459922

Opioid Use Disorder Sleep Disturbance

RECRUITING NA

Transdermal Electroacupuncture for Opioid Detoxification

NCT00742170

Opioid Dependency

COMPLETED PHASE1/PHASE2

Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Opioid Use Disorder

NCT04495673

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project is to demonstrate that a novel treatment for opiate addiction is safe and far superior to a sham comparison treatment. The treatment is hoped to significantly aid in the battle against the opioid epidemic that is ravaging much of the country and the world. The treatment consists of using a 4-minute application of transcranial photobiomodulation, near infra-red mode, through a supra-luminous LED, to one side of the forehead over the brain hemisphere that we determine (through a proprietary test) to have a more positive emotional valence. Based on preliminary data, we anticipate that the treatment will be very effective in reducing drug cravings, anxiety, and depression as well as in reducing relapses. Aim I will offer twice-weekly treatments to two groups, active and sham, for 4-weeks and will look specifically for differences in opioid cravings, anxiety, depression, and opioid use. The investigators will evaluate participants weekly for safety and efficacy for 3-weeks post-treatment. In Aim II a highly-regarded product engineer will work with the company to design a marketable product that may have patentable elements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid-use Disorder Opioid Dependence Opioid Abuse

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

20 participants will receive twice a week active treatment for 4-weeks of a 4-minute near-infrared light treatment through the forehead to a brain hemisphere and 20 will receive a sham treatment.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

The sham is created by putting a piece of aluminum foil over the light-emitting diode. It will be placed there or not placed there by a 3rd party so that neither the participant nor the outcomes assessor will know the condition of the study.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reduction in opioid cravings and use

These participants will receive twice-weekly transcranial photobiomodulation with and 810 nm LED for 4 min for a delivery to the brain of 2.1 J/cm2. The treatment will last 4 weeks. We anticipate a 60% reduction in opioid cravings in this group. We anticipate a reduction of at least 1.6 days of use per week on average.

Group Type ACTIVE_COMPARATOR

supra-luminous LED

Intervention Type DEVICE

810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.

Small reduction in opioid cravings and use

Sham condition.

Group Type PLACEBO_COMPARATOR

Sham

Intervention Type DEVICE

Light-emitting diode covered with aluminium foil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

supra-luminous LED

810 nm light-emitting diode for the delivery of 2.1 J/cm2 to the brain.

Intervention Type DEVICE

Sham

Light-emitting diode covered with aluminium foil

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

unilateral trancranial photobiomodulation, near-infrared mode

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients must between the ages of 18 and 70
* meet criterion for a history of Opioid Use Disorder (OUD) on a Diagnostic Interview.
* have opioid cravings
* Enrollment will be made without regard to gender or ethnicity.
* Patients who are receiving treatment for OUD or other psychiatric disorders, either psychological or pharmacological treatments, may continue their treatment during the time of the study but will be asked to try not to alter their treatment from the onset of the experiment until its conclusion. The statistical analysis will include covariates for doses of buprenorphine and methadone and use of non-prescribed opioids

Exclusion Criteria

* past history of a psychotic disorder (including schizophrenia or schizoaffective disorder)
* history of violent behavior
* history of a past suicide gesture or attempt, a history of current suicidal ideation, \*history of a neurological condition (e.g. epilepsy, traumatic brain injury, stroke), \*pregnancy
* current acute or chronic medical condition requiring a medication that has psychological side-effects.
* impaired decision-making capacity in the judgment of the investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No